Literature DB >> 30039457

Thrombogenicity and long-term cytokine removal capability of a novel asymmetric triacetate membrane hemofilter.

Andreas Körtge1, Thomas Wild2, Benjamin Heskamp2, Manuel Folk2, Steffen Mitzner2,3, Reinhold Wasserkort2.   

Abstract

Hemofilters applied in continuous renal replacement therapies (CRRTs) for the treatment of acute kidney injury must meet high standards in biocompatibility and permeability for middle and large molecules over extended treatment times. In general, cellulose-based membranes exhibit good biocompatibility and low fouling, and thus appear to be beneficial for CRRT. In this in vitro study, we compared a novel asymmetric cellulose triacetate (ATA) membrane with three synthetic membranes [polysulfone (PS), polyethersulfone (PES), and polyethylenimine-treated acrylonitrile/sodium methallyl sulfonate copolymer (AN69 ST)] regarding thrombogenicity and cytokine removal. For thrombogenicity assessment, we analyzed the thrombin-antithrombin complex (TAT) generation in human whole blood during 5 h recirculation and filtration. Sieving coefficients of interleukin-6 (IL-6), IL-8, IL-10, and tumor necrosis factor-alpha (TNF-α) were determined using human plasma as test fluid. ATA and AN69 ST membrane permeability were determined also during long-term experiments (48.5 h). ATA exhibited the lowest TAT generation (6.3 µg/L at 5 h), while AN69 ST induced a pronounced concentration increase (152.1 µg/L) and filter clogging during 4 out of 5 experiments. ATA (IL-8: 1.053; IL-6: 1.079; IL-10: 0.898; TNF-α: 0.493) and PES (0.973; 0.846; 0.468; 0.303) had the highest sieving coefficients, while PS (0.697; 0.100; 0.014; 0.012) and AN69 ST (N/A; 0.717; 0; 0.063) exhibited lower permeability. Long-term experiments revealed stronger fouling of the AN69 ST compared to the ATA membrane. We observed the highest permeability for the tested cytokines, the lowest thrombogenicity, and the lowest fouling with the ATA membrane. In CRRT, these factors may lead to increased therapy efficacy and lower incidence of coagulation-associated events.

Entities:  

Keywords:  Acute kidney injury; Continuous renal replacement therapy; Cytokine removal; Membrane fouling; Thrombogenicity

Mesh:

Substances:

Year:  2018        PMID: 30039457     DOI: 10.1007/s10047-018-1062-1

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  16 in total

1.  Analysis of protein fouling during ultrafiltration using a two-layer membrane model.

Authors:  R F Boyd; A L Zydney
Journal:  Biotechnol Bioeng       Date:  1998-08-20       Impact factor: 4.530

Review 2.  Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis.

Authors:  W R Clark; R J Hamburger; M J Lysaght
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

Review 3.  Mediators of inflammation in acute kidney injury.

Authors:  Ali Akcay; Quocan Nguyen; Charles L Edelstein
Journal:  Mediators Inflamm       Date:  2010-02-21       Impact factor: 4.711

4.  Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations.

Authors:  Luisa Pieroni; Stefano Levi Mortera; Viviana Greco; Vittorio Sirolli; Maurizio Ronci; Paolo Felaco; Giorgio Fucci; Silvia De Fulviis; Renato Massoud; Stefano Condò; Ambrogio Capria; Nicola Di Daniele; Sergio Bernardini; Andrea Urbani; Mario Bonomini
Journal:  Mol Biosyst       Date:  2015-06

5.  Cellulose triacetate dialyzer reduces platelet loss during continuous veno-venous hemofiltration.

Authors:  Shuangxin Liu; Wei Shi; Xinling Liang; Yong Su; Yongzhen Liang; Bin Zhang; Zhiming Ye; Lixia Xu; Yunfeng Xia; Chaoshen He; Jianchao Ma; Yiming Tao; Hen Ye; Hui Li
Journal:  Blood Purif       Date:  2010-05-20       Impact factor: 2.614

Review 6.  Fundamental Characteristics of the Newly Developed ATA™ Membrane Dialyzer.

Authors:  Takashi Sunohara; Toshiaki Masuda
Journal:  Contrib Nephrol       Date:  2016-12-12       Impact factor: 1.580

7.  Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation.

Authors:  Takahiro Kuragano; Tsutomu Kuno; Yoshiko Takahashi; Chii Yamamoto; Yuji Nagura; Susumu Takahashi; Katsuo Kanmatsuse
Journal:  Blood Purif       Date:  2003       Impact factor: 2.614

8.  Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy.

Authors:  A Fujimori; H Naito; T Miyazaki
Journal:  Artif Organs       Date:  1998-12       Impact factor: 3.094

Review 9.  Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis.

Authors:  Claudio Ronco; Ciro Tetta; Filippo Mariano; Mary Lou Wratten; Monica Bonello; Valeria Bordoni; Ximena Cardona; Paola Inguaggiato; Lidia Pilotto; Vince d'Intini; Rinaldo Bellomo
Journal:  Artif Organs       Date:  2003-09       Impact factor: 3.094

Review 10.  Renal replacement therapy in acute kidney injury: controversy and consensus.

Authors:  Claudio Ronco; Zaccaria Ricci; Daniel De Backer; John A Kellum; Fabio S Taccone; Michael Joannidis; Peter Pickkers; Vincenzo Cantaluppi; Franco Turani; Patrick Saudan; Rinaldo Bellomo; Olivier Joannes-Boyau; Massimo Antonelli; Didier Payen; John R Prowle; Jean-Louis Vincent
Journal:  Crit Care       Date:  2015-04-06       Impact factor: 9.097

View more
  2 in total

1.  Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies.

Authors:  Ting Lin; Li Song; Renwei Huang; Ying Huang; Shuifu Tang; Qizhan Lin; Ying Zhang; Xingbo Wu; Hui Liang; Yuchi Wu; Yuanhan Chen; Huaban Liang; Jianchao Ma; Zhonglin Feng; Zhuo Li; Lixia Xu; Xia Fu; Zhiming Ye; Shuangxin Liu; Xinling Liang
Journal:  BMC Nephrol       Date:  2019-12-19       Impact factor: 2.388

2.  Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease.

Authors:  Kanako Takahashi; Hiroyuki Inoue; Masumi Kishimoto; Ryuichi Nakayama; Takehiko Kasai; Naofumi Bunya; Keisuke Harada; Shuji Uemura; Eichi Narimatsu
Journal:  Ren Replace Ther       Date:  2022-09-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.